Project Grant R01HL185515
Award Date 8/5/26
Completion Date 4/30/31
Dollars Obligated $768K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $873,801 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epithelial reprogramming mechanisms that distinguish normal regenerative repair from pathologic fibrotic remodeling in chronic lung diseases, particularly idiopathic pulmonary fibrosis. The research examines how airway and alveolar epithelial stem and progenitor cells progress through intermediate...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart Lung and Blood Institute awarded Weill Medical College of Cornell University $936,356 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, for the PE-TRACT Extend Study, a prospective cohort investigation of chronic thromboembolic disease following intermediate-risk pulmonary embolism treatment. The study extends the NHLBI-funded PE-TRACT randomized trial of catheter-directed therapy for acute PE by following the parent study population beyond the...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Cornell University $734,475 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanobiological regulation of ventricular maturation. The research will test the hypothesis that local mechanical stress operates a Piezo-Notch-YAP mechanobiological switch governing temporal compact and trabecular ventricular wall growth versus structural maturation dynamics. The...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $704,851 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance tissue characterization methods for prognostication and therapeutic response prediction in functional tricuspid regurgitation. The project leverages newly developed CMR techniques optimized for the thin-walled right ventricle, including high-resolution 3D navigator late...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,541,783 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate novel roles of the thrombin receptor protease-activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome. The research uses mouse models to examine PAR1's role in button junction formation during lung injury. The work identifies how...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $816,853 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 14, 2026, to investigate the role of endothelial ceramides in coronary atherosclerosis development and progression. The research tests the hypothesis that very long chain ceramides protect against coronary atherosclerosis by preserving endothelial cell resilience to atherogenic stressors through KLF2 expression....